Sign in

    Shirley Chen

    Wall Street Analyst at Barclays

    Shirley Chen is a Wall Street Analyst at Barclays, specializing in general sector research with coverage of three specific stocks. She has maintained a 27.27% success rate according to TipRanks, with a rating of 1.10 stars, reflecting a track record of modest performance among her peers. While comprehensive details about her career timeline or prior experience are not publicly disclosed, her current role indicates a focus on quantitative analysis within the investment research team. Professional credentials such as FINRA registration or securities licenses are not listed in publicly available sources.

    Shirley Chen's questions to Sanofi (SNY) leadership

    Shirley Chen's questions to Sanofi (SNY) leadership • Q2 2025

    Question

    Shirley Chen of Barclays questioned how Sanofi plans to mitigate pricing pressure in the flu vaccine market and asked for the key drivers supporting the high single-digit sales guidance despite these headwinds.

    Answer

    EVP of Vaccines Thomas Triomphe attributed the flu sales decline to a one-off price reset in Germany and U.S. competition, but expects to maintain market share. CFO François Roger expressed confidence in the full-year guidance, citing strong H1 performance, continued robust growth from Dupixent, and new launches now contributing nearly a quarter of the company's growth.

    Ask Fintool Equity Research AI

    Shirley Chen's questions to Sanofi (SNY) leadership • Q4 2024

    Question

    Shirley Chen from Barclays asked about the timing of contracting for the next Beyfortus season, its first-mover advantage, pricing strategy, and concerns about broader vaccine hesitancy.

    Answer

    Executive Thomas Triomphe noted that Beyfortus ordering is not seasonal like flu and that its first-mover advantage comes from its strong real-world evidence and physician familiarity, with no price erosion expected in 2025. He acknowledged vaccine hesitancy is a concern but believes the recent comeback of diseases like influenza serves as a 'good wake-up call' about the importance of vaccination.

    Ask Fintool Equity Research AI

    Shirley Chen's questions to NOVARTIS (NVS) leadership

    Shirley Chen's questions to NOVARTIS (NVS) leadership • Q2 2025

    Question

    Shirley Chen from Barclays asked about the slowdown of Cosentyx in China, its impact on the broader portfolio, Novartis's strategy to adapt, and the potential for out-of-pocket models for other products.

    Answer

    CEO Vasant Narasimhan acknowledged a sector-wide slowdown in China's pharmaceutical spending, which has impacted high-volume products like Cosentyx. He stated that Novartis still expects high single-digit to low-teens growth in the region. He also highlighted the success of Leqvio's out-of-pocket model as a positive development that informs future commercial strategies in China.

    Ask Fintool Equity Research AI